Table 2 Relationship between expression of TS and p53, and effects of neoadjuvant S-1/cisplatin chemotherapy in pretreatment biopsy specimens

From: Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer

Marker expression

Histological responders (%)* (n =13)a

Histological non-responders (%)** (n =25)a

Control untreated cases (%)*** (n =48)a

P -value

    

* vs **

* vs ***

** vs ***

TS

 High

1 (8)

7 (28)

15 (31)

0.22

0.15

>0.99

 Low

12 (92)

18 (72)

33 (69)

   

p53

 High

1 (8)

14 (56)

14 (29)

<0.01b

0.16

<0.05b

 Low

12 (92)

11 (44)

34 (71)

   

TS- and/or p53-high

1 (8)

19 (76)

26 (54)

<0.0001b

<0.005b

0.08

TS- and p53-low

12 (92)

6 (24)

22 (46)

   
  1. aPretreatment biopsy specimens were available for analysis in 38 out of 41 patients with neoadjuvant chemotherapy, and 48 out of 51 control patients without neoadjuvant chemotherapy.
  2. bStatistically significant.
  3. *Responders, **Non-responders, ***Control cases.
Back to article page